Back to top
more

Compugen (CGEN)

(Delayed Data from NSDQ)

$1.46 USD

1.46
184,093

-0.02 (-1.35%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $1.46 0.00 (0.00%) 4:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Day One (DAWN) In-Licenses MabCare Cancer Candidate, Stock Up

by Zacks Equity Research

Day One (DAWN) gains 11% on in-licensing exclusive worldwide rights to MabCare???s MTX-13, which is set to begin clinical studies for adult and pediatric solid tumor indications.

Zacks Equity Research

Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals

by Zacks Equity Research

Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.

Zacks Equity Research

Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals

by Zacks Equity Research

Aerovate's (AVTE) shares plunge 93% as its lead candidate, AV-101, fails to meet the primary and secondary endpoints in the phase IIb/III study to treat pulmonary arterial hypertension patients.

Zacks Equity Research

Apellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study

by Zacks Equity Research

Apellis (APLS) rises 3.3% as the treatment of GA patients with Syfovre demonstrates a visual function benefit in a prespecified endpoint at month 36 in a late-stage, long-term extension study.

Zacks Equity Research

ChromaDex (CDXC) Up as Ataxia Candidate Gets Orphan Drug Tag

by Zacks Equity Research

ChromaDex (CDXC) rises 12% as the FDA grants the Orphan Drug Designation and the Rare Pediatric Disease Designation to its investigational candidate, NRC, to treat ataxia telangiectasia.

Zacks Equity Research

Repare (RPTX) Up 14% as Ovarian Cancer Combo Gets Fast Track Tag

by Zacks Equity Research

Repare (RPTX) rises 14% as the FDA grants Fast Track designation to its investigational lunresertib/camonsertib combo to treat adult ovarian cancer patients in the United States.

Zacks Equity Research

Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals

by Zacks Equity Research

Annexon (ANNX) jumps 31% after meeting the primary and key secondary endpoints with the low dose of its lead candidate, ANX005, in the phase III study for Guillain-Barre syndrome.

Zacks Equity Research

Intellia (NTLA) Up on Upbeat Long-Term Angioedema Study Data

by Zacks Equity Research

Intellia (NTLA) gains 10% after reporting encouraging long-term efficacy data from the phase I portion of its early to mid-stage study evaluating NTLA-2002 for treating hereditary angioedema.

Zacks Equity Research

Compugen (CGEN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Compugen (CGEN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks Equity Research

Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Compugen (CGEN) delivered earnings and revenue surprises of 20% and 8.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Are You Looking for a Top Momentum Pick? Why Compugen (CGEN) is a Great Choice

by Zacks Equity Research

Does Compugen (CGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

BOX Gears Up to Report Q4 Earnings: Here's What to Expect

by Zacks Equity Research

BOX's fourth-quarter fiscal 2024 results are likely to reflect gains from the growing adoption of content cloud solutions.

Zacks Equity Research

Will Petrobras (PBR) Report Q4 Earnings Beat on Output Gains?

by Zacks Equity Research

Petrobras (PBR) beat the Zacks Consensus Estimate in two of the last four quarters and missed in the other two, which resulted in an earnings surprise of 3.8%, on average.

Zacks Equity Research

Is a Surprise Coming for Compugen (CGEN) This Earnings Season?

by Zacks Equity Research

Compugen (CGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

On Puma Biotechnology's (PBYI) fourth-quarter 2023 earnings call, investors' focus is likely to be on the sales performance of its sole marketed cancer drug, Nerlynx.

Zacks Equity Research

Baidu (BIDU) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Baidu's (BIDU) fourth-quarter results are likely to reflect the benefits of its AI business and growing autonomous driving efforts amid uncertainties in China.

Zacks Equity Research

Vipshop (VIPS) to Post Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Vipshop's (VIPS) fourth-quarter results are expected to reflect strength in its merchandising strategy and discount retail business amid macroeconomic challenges in China.

Zacks Equity Research

ACM Research (ACMR) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

ACM Research's (ACMR) fourth-quarter 2023 results are expected to reflect gains from semiconductor, ECP and advanced packaging businesses.

Zacks Equity Research

What to Look for in Crescent Point's (CPG) Q4 Earnings?

by Zacks Equity Research

Lower price realizations and an upward cost trajectory are likely to have dented Crescent Point Energy's (CPG) fourth-quarter results.

Zacks Equity Research

Agilent Technologies (A) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Agilent's (A) results for the fiscal first quarter are expected to reflect strength across ACG amid weakness in the LSAG and DGG segments.

Zacks Equity Research

What's in Store for Qurate Retail (QRTEA) in Q4 Earnings?

by Zacks Equity Research

Qurate Retail's (QRTEA) fourth-quarter 2023 results are likely to reflect strength in gardening, food and kitchen, and home decor categories.

Zacks Equity Research

Ginkgo (DNA) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Ginkgo's (DNA) fourth-quarter earnings call, investor focus is likely to be on the sales performance of its two business units, Biosecurity and Cell Engineering.

Zacks Equity Research

Eton Pharma (ETON) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Eton Pharma's (ETON) revenues in the fourth quarter of 2023 are expected to have been driven by the sales of its marketed products.

Zacks Equity Research

Compugen (CGEN) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does Compugen (CGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Biotech Stock Roundup: CGEN Up on GILD Deal, MRNA Gains on Study Data & More

by Zacks Equity Research

Compugen (CGEN) and Moderna (MRNA) are in the news on collaboration and study updates, respectively.